CCG 224061
CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC50 of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes. CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2055990-82-2
- Formel: C19H20FN3O
- Molecular Weight:325.39
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
GRK2 0.066 μM (IC50) |
In Vitro
CCG 224061 (E18) potently and selectively inhibits GRK2 with an IC50 of 0.07 μM, while it shows weak inhibitory effects on GRK5 (IC50 12.8 μM) and GRK1 (IC50 65.7 μM)[1].
CCG 224061 (5 min) potently inhibits GRK2 (IC50 = 0.066 μM) and exhibits activity against GRK1 (IC50 = 6.4 μM), GRK5 (IC50 = 1.3 μM), PKA (IC50 = 3.1 μM) and ROCK1 (100% inhibition at 10 μM) in in vitro purified kinase assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | AUC0-∞ |
|---|---|---|---|
| Mice[2] | 10 mg/kg | i.p. | 731 ng·h/mL |
Chemical Information
-
CAS. Nr. 2055990-82-2
-
Molecular Weight 325.39
-
Formel C19H20FN3O
-
SMILES
C(OC=1C=C2C(=CC1)NN=C2)[C@H]3[C@@H](CCNC3)C4=CC=C(F)C=C4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)